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Overview of CFTR Modulators 
and Gene Therapy
Catherine Rang, Tom Kotsimbos and John Wilson
Abstract
Individuals with cystic fibrosis (CF) have seen a substantial change in their life 
expectancy since the introduction of coordinated multi-disciplinary care. This is 
expected to continue with the recent availability of treatment options that focus on 
targeting the underlying genetic defect. Two different approaches to altering the 
consequence of mutations in the cystic fibrosis transmembrane conductance regula-
tor (CFTR) gene include “genetic medicines”, in particular gene therapy, and CFTR 
modulator agents. Gene therapy requires further development prior to it being a 
treatment option because to date the best clinical outcomes are that of a reduction 
in the rate of lung function decline. Modulator therapies on the other hand have 
provided exciting results in both clinical trials and real-world settings. Potentiator 
agents alter dysfunctional ion channel gating and are suitable for gating mutations. 
Corrector agents target abnormal protein trafficking. The combination of potentia-
tor and corrector therapy provides options for homozygotes with the commonest 
mutation Phe508del and for those with Phe508del and some residual function 
mutations. Newer modulator therapies are in continued development with progres-
sively impressive outcomes. It is likely that future CF care will comprise of personal-
ized strategies with the focus centered upon an individual’s specific mutations.
Keywords: cystic fibrosis, CF pathophysiology, CFTR modulator therapy,  
gene therapy
1. Introduction
Cystic fibrosis (CF) is an autosomal recessive condition that results from 
mutations in the cystic fibrosis transmembrane conductor regulator (CFTR) gene 
located on the long arm of chromosome 7. The gene was identified 30 years ago 
and since then over 2000 CFTR mutations have been discovered with more than 
300 known to be disease causing [1, 2]. The commonest mutation is Phe508del 
(F508del; c.1521_1523delCTT), where a phenylalanine is substituted at position 508 
on chromosome 7. Worldwide approximately 80–90% of individuals with CF have 
at least one copy of the Phe508del-CFTR mutation, although mutation rates varying 
depending upon the population cohort [3–5].
CF is a multi-system disease with the highest disease prevalence being in 
Europe, North America and Australia. There are approximately 80,000 people with 
CF worldwide. The disease is characterized by chronic airway infection, pancreatic 
insufficiency and malnutrition, diabetes, liver disease, absent vas deferens and 
premature death.
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Due to the multi-system nature of the disease, treatment has classically focused 
on therapies and systems of care that aim to improve salt and fluid balance and 
nutritional status, alongside reducing airway inflammation and lung parenchymal 
destruction. These multi-disciplinary management approaches have been instru-
mental in the improvements seen in life expectancy. The median predicated survival 
of an individual born today with CF is 47 years, compared with 20 years at the time 
when CFTR was discovered in 1989 [2]. However, to have a true impact upon the 
management of these patients and to alter the disease trajectory, treatment options 
needed to also include approaches targeting the underlying genetic mutation.
This chapter will include a review of the structure of the CFTR protein, its 
biosynthesis and the pathophysiology of CF so as to provide a basis from which to 
discuss the various therapeutic strategies that have more recently been developed 
for modulating CFTR protein function. Also, a discussion regarding gene therapy 
will be included so as to enable contrasts and comparisons to be made between the 
different therapies being evolved to address the underlying genetic defect in CF 
patients.
2. Pathophysiology of cystic fibrosis
2.1 CFTR protein structure
CFTR codes for a complex protein, which is present in every nucleated cell of 
the body, however it is normally concentrated on the apical membrane of epithelial 
cells, primarily within the glandular epithelia. High expression of this apical anion 
channel is seen within the lungs, pancreas, gastrointestinal tract, vas deferens and 
sweat glands; reflecting the main organs affected in CF [6].
The CFTR protein is a large, unique member of the subclass C family of the ATP 
binding cassette (ABC) transporter proteins, which functions as an ion channel 
rather than an active transporter protein [7–9]. It consists of two membrane-
spanning domains (MBDs) that form the ion channel. These domains are both 
connected to two cytoplasmic nucleotide-binding domains (NBD1 and NBD2), 
which function to gate the channel. This conformation of two MBDs and two NBDs 
that hydrolyse ATP are typical for most ABC transporters. However, CFTR has an 
additional cytoplasmic regulatory domain (R domain), inserted between NBD1 
and MSD2 linking the two transporter domains. Phosphorylation of the R domain 
by protein kinase A enables channel opening to occur and channel activity is 
increased upon phosphorylation. Once phosphorylation has taken place, ATP binds 
to the NBDs resulting in the two NBDs forming tightly interacting dimers, which 
gates the channel. These movements are transmitted to the MBDs causing the ion 
pore to open. Channel closure results from ATP hydrolysis. The exact mechanisms 
underlying the regulation of the R domain and ATP-dependent gating are still not 
completely understood [10, 11].
2.2 CFTR protein synthesis
CFTR protein synthesis is a complex process, in part related to the size of the 
functional protein. As with all protein synthesis, transcription of the CFTR DNA 
takes place within the nucleus to create the messenger RNA (mRNA), which is trans-
ported across the nuclear membrane to the cytosolic ribosomes. There the initiation 
of translation occurs to create a 1480-amino acid polypeptide chain based upon the 
genetic code. Initially a 135- to 140-kDa core-glycosylated precursor is produced 
(immature CFTR). CFTR biosynthesis then proceeds through the endoplasmic 
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reticulum (ER) followed by the Golgi apparatus to a mature 150- to 160-kDa CFTR 
form which has undergone conformational folding [12]. During the secretory 
pathway through the ER to the Golgi and then on to the cell membrane various post-
translational modifications take place (Figure 1).
The maturation process to create the final relatively compact CFTR protein 
structure is inefficient and slow. Less than 30% of newly synthesized wild-type (wt) 
immature CFTR molecules develop into mature CFTR proteins. For folding of the 
polypeptide chain to occur chaperones are required, in particular the 70 k-Da heat 
shock proteins (HSP70) and calnexin. In cells of individuals with the Phe508del-
CFTR mutation, almost all immature molecules fail to reach final maturity and thus 
are degraded. This is the due to the quality control mechanisms in place within the 
ER, specific signals and distinct processes exist that recruit misfolded proteins to the 
ER-associated degradation as a final endpoint. These proteins are then directed for 
degradation via the ubiquitin-proteasome pathway [12–14] (Figure 1).
Certain steps within the CFTR biosynthesis pathway are still unknown, how-
ever, data does support each domain folding independently. The native structure 
develops through a co-translational mechanism, possibly together with post-
translational processes that take place to create the compactly folded domains. 
Domain-domain interactions are key in the creation of conformationally correct 
CFTR [15]. Furthermore, it appears that CFTR is more sensitive to mutations in 
NBD1 compared with homologous mutations in NBD2, leading to issues with the 
conformational maturation of the whole CFTR protein. For example, the deletion 
of the Phe508 does not appear to grossly alter the structure of NBD1 but subsequent 
issues arise during the maturation process, possibly through the disruption of the 
interaction between NBD1 and NBD2 and despite each domain folding indepen-
dently. Maturation thus requires precise folding of each domain together with the 
Figure 1. 
Cell biology of CFTR - abnormal CFTR protein results in the uncoupling of CFTR dependent processes at all 
levels from intracellular dynamics to cell membrane function. Reproduced with permission of the © ERS 2020: 
European Respiratory Journal; DOI: 10.1183/13993003.02443-2019: Accepted for publication and in press.
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correct inter-domain assembly to create a stable structure that will not be submitted 
to ER-associated degradation [13, 16].
If the protein passes through all the checkpoint steps within the ER, it can exit 
and be transported through the Golgi apparatus in vesicles where the removal and 
addition of new glycan units takes place, increasing the molecular size of CFTR. It 
is becoming clear that some wt-CFTR might bypass these processes in the delivery 
pathway to the plasma membrane. Once at the membrane, levels of CFTR vary 
depending upon the balance of anterograde trafficking, endocytosis and recycling. 
Recycling of internalized CFTR to the plasma membrane is thought to assist with 
sustaining a functional pool of CFTR at the membrane level [15].
2.3 Pathophysiology
CFTR functions as a chloride and bicarbonate channel. Loss of functional CFTR 
proteins result in reduced chloride efflux from epithelial cells leading to depletion 
of the cell surface fluid and altering its pH and osmolarity. CFTR also regulates the 
activity of various other key processes within the cell, including the activity of other 
ion channels, such as the sodium epithelial channel (ENaC; the amiloride-sensitive 
sodium channel). Suppressed CFTR activity can lead to unopposed reabsorption of 
sodium and water via ENaC, causing additional dehydration of the cell surface layer 
[6]. Mucociliary clearance is further delayed due to abnormally adherent mucus. 
Dysfunctional CFTR also impacts upon mitochondrial function, the innate immunity 
and dysregulates inflammation [17–19]. Within the airways, this results in an environ-
ment that is susceptible to unchecked inflammation and chronic bacterial infection.
Although multiple processes both intra- and extra-cellularly are altered by 
dysfunctional CFTR proteins, chloride transport at the cell surface is generally con-
sidered to be the major driver of the pathophysiological disease. Functional chloride 
channel changes are thus likely to represent an easily accessible surrogate marker 
of all processes affected in CF, with sweat chloride testing being relatively easy to 
perform. In vitro studies have shown that only 6–10% of residual CFTR function is 
required to restore chloride transporting properties seen in 100% correct cells, with 
cell-cell coupling providing a means of amplification of the functional properties 
[20]. Individuals with CF who have approximately 10% CTFR expression per cell do 
not generally develop lung disease or the full range of classical CF disease. To date, 
it is unclear whether low level expression (10%) of CFTR in all cells is comparable 
to 10% of CFTR cells with full correction [21]. In addition, even individuals with a 
single CFTR mutation may have organ dysfunction in the context of a second “hit” 
such as smoking [22].
The general identification of mutations in the structure of CFTR has been 
centralized for clinician reference. CFTR2.org identifies over 2000 variants of the 
protein, of which over 400 are disease-associated. The majority of variants are rare 
and not confirmed to be disease-associated, however the large number of variants 
indicates the lack of stability of the CFTR gene in population dynamics [1].
3. Classification of CFTR mutations
Classification systems of common CFTR mutations have been developed to 
assist with understanding of the consequential molecular defect. The established 
classification system includes six different classes (Figure 2). Different mutations 
can result in no functional protein production, impaired protein trafficking, altered 
channel gating, decreased channel conductance, reduced protein synthesis and 
decreased protein stability [6]. Each class confers a different disease severity, which 
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is related to the degree of CFTR dysfunction and has prognostic implications for 
patients. However, each mutation may have features of more than just one class. 
For example, Phe508del is predominately a class II mutation but also has both class 
III and class VI properties. More recently, other classification systems have been 
proposed, which subdivide class I mutations (no functional CFTR protein) into 
two groups so as to take into account whether the mutation leads to no mRNA or no 
functional protein [23].
4. Genetic medicines
Traditional CF care has focused upon the management of the systems affected 
in individuals with CF. However, the identification of the CFTR gene enabled 
researchers to focus on treatments strategies, which could address the underlying 
genetic defect. The major cause of morbidity and mortality in CF is secondary to 
lung disease. Hence, if abnormal CFTR in the lungs could be replaced with wt-
CFTR during the neonatal period, prior to parenchymal lung damage or bacterial 
colonization, morbidity and mortality could be significantly altered within the 
CF population [24]. Various approaches have been investigated within the field of 
“genetic medicines” and unfortunately to date none are a viable treatment option 
outside of clinical trials.
Figure 2. 
CFTR classification table. The classification systems divide mutations into discrete groups determined by 
the predominant CFTR defect. However, these systems may not be mutually exclusive for all mutations. 
For example, the p.Phe508del-CFTR is predominately class II but does also have some class III and class 
VI properties. Reproduced with permission of the © ERS 2020: European Respiratory Journal; DOI: 
10.1183/13993003.02443-2019: Accepted for publication and in press.
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“Genetic medicines” comprise of four different treatment approaches:
i. Gene therapy: the delivery of wt-CFTR to the cell nucleus resulting in the 
production of normal CFTR protein;
ii. mRNA therapy: the delivery of correct CFTR mRNA to the cytoplasm 
resulting in the production of normal CFTR protein;
iii. Gene editing: repair of the mutant CFTR DNA with normal CFTR pro-
tein resulting. This requires wt-CFTR DNA to be delivered to the nucleus 
together with mRNA encoding a nuclease that causes a break in the DNA 
leading to recombination occurring;
iv. mRNA editing: CFTR mRNA delivery to the cytoplasm leading to repair of 
the CFTR mRNA [21].
The potential benefit of these therapies is that theoretically they should be suit-
able for the treatment of all individuals with CF, regardless of genotype. Currently 
gene therapy has made the greatest advancement towards being a clinical treatment 
and so the main focus of this section will be around gene therapy.
As the respiratory system is so central to CF disease and because initial thoughts 
were that gene therapy targeting the lungs would be easy to deliver, locally directed 
gene therapy to the respiratory epithelium was the method of choice. Furthermore, 
gene therapy can complement any CFTR causing mutation. However, for such 
treatment to be successful various issues had to be addressed, including the choice 
of delivery vector, method of delivery to the airways, translocation of the genetic 
information and ultimately ensuring that there was appropriate expression of the 
normalized CFTR gene [25]. These various issues will each be discussed to provide 
insight in the difficulties experienced in trying to develop “genetic medicines.”
The lungs are comprised of terminally differentiated epithelial cells, which are 
slowly replaced by stem/progenitor cells. Any form of gene therapy must be able to 
be either repeatedly delivered to the terminally-differentiated cell surface or be able 
to alter the stem/progenitor cells within the lungs. However, the lung has evolved 
physical and immune mechanisms to protect against pathogens and particulate 
materials, which impacts upon choice of vector delivery [26, 27].
Delivery vectors are largely either viral or non-viral in nature with viral ones 
felt to be more efficient. This is because they have evolved to overcome the barrier 
mechanisms present within the lungs. Adenoviruses (Ad) and adeno-associated 
viruses (AAV) have a natural trophism for the lungs, are DNA-based and thus were 
the initial choices to study. Adenoviruses are small in size and thus to insert the 
CFTR DNA correctly within the adenoviral genome, viral DNA must be removed, 
impacting upon the viral cytopathic effect. These vectors were found to have poor 
efficacy due to the pre-existing and induced immune responses, and thus cannot be 
repeatedly administered as required for these treatments because of the short life 
span of bronchial epithelial cells.
Other viral vectors that have been investigated are recombinant lentivirus (rLV). 
These agents are RNA-based and can integrate into the genome. This can be advan-
tageous as it ensures that the vector is passed down the cell lines during division but 
it also does have the risk of inducing insertional mutagenesis [21, 26, 28]. However, 
ultimately other vectors were needed to be formulated, ones which had a minimal 
risk of immunogenicity and thus could be repeatedly administered.
Non-viral gene transfer agents complexed to plasmid DNA were therefore devel-
oped [21, 29]. These have been more successful than their viral vector counterparts 
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and have been investigated in Phase IIb studies. Patients who were 12 years and 
older were treated with the non-viral CFTR gene-liposomal complex pGM169/
GLG7A as a nebulized therapy over a one-year period. The repeated nebulization 
each month resulted in a reduction in the progression of CF lung disease by a 
modest amount when compared with placebo. The percentage change in the forced 
expiratory volume in 1 second (FEV1) over 12 months was −0.4% versus −4.0% 
in the placebo arm. Hence, although no improvement in lung function was seen, 
this study was promising as rate of lung function decline does impact morbidity 
and mortality in CF. However, disappointingly also there were no improvements in 
quality of life measures [30].
As described in the above study the agents utilized were delivered via inhala-
tion methods. This has been found to be the easiest method for repeated treatment 
applications. However, difficulties have arisen ensuring adequate lung deposition 
of drug, related to particle size and the type of nebulisers used. Additionally, any 
aerolised drug delivered must retain its biological function post-delivery [31, 32].
Other strategies for ensuring corrected CFTR protein production is through 
mRNA therapy and mRNA repair as described above. The benefit of these 
approaches is that they do not require translocation of the therapy across the 
nuclear membrane. Nanoparticle-chemically modified mRNA has resulted in lung 
function improvements in animal models without any immune reactions despite 
repeated applications. Also, there is evidence that these therapies can restore chlo-
ride channel activity [33, 34]. Ongoing work and investigation are required prior to 
these options being viable in the clinical setting.
5. CFTR modulator agents
CFTR modulator agents are small molecules which ‘modulate’ the function 
of the abnormal CFTR protein. Unlike gene therapy, they do not alter the CFTR 
gene. However, these agents do manipulate the underlying genetic consequence 
of CF mutations. Currently two different classes of modulator agents have been 
developed;
i. potentiators which ‘potentiate’ the cAMP-mediated gating of the CFTR 
channel; and
ii. correctors which ‘correct’ defects in protein trafficking.
5.1 CFTR modulator drug design
High-throughput drug discovery programs enabled the development of such 
agents. These discovery programs were established to identify active compounds 
(“hits”) from large chemical libraries suitable for industrial-scale screening. 
High-throughput screening (HTS) assays need to be robust, have high throughput 
using small sample volumes together with adequate sensitivity, reproducibility and 
accuracy to ensure differentiation between a very large amount of compounds [35]. 
Ion channels are key targets for drug design and thus HTS have been an important 
part of such drug discovery processes, including for CF [36, 37].
The two classes of small molecules for CFTR protein modulation were identified 
via HTS techniques from libraries that consisted of chemically diverse drug-like 
and lead-like compounds acquired from both commercial vendors and internal 
medicine chemistry programs. If compounds had an activity >2.5 standard devia-
tions (SD) from the mean, then they received further testing. For example, from 
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~164,000 synthetic compounds initial screened, approximately 100 were suitable 
for further study in one study [38]. The molecules identified were optimized and 
evaluated in terms of pharmacokinetics and toxicology [39, 40].
5.2 Potentiator therapy
The first small molecule clinically available for individuals with CF following 
HTS was Ivacaftor (Kalydeco®). It is an oral CFTR potentiator agent, which can be 
given to CF individuals who have gating, residual function, splice or conduction 
mutations [41–44]. It was originally developed for the Gly551Asp-CFTR muta-
tion (G551D; a class III mutation), which results in defective cAMP CFTR channel 
gating. The gating of the channel reflects the opening and closed states of the CFTR 
protein. If gating is defective, then a low probability of CFTR channel opening 
occurs and in turn reduced overall CFTR function. Ivacaftor treatment results in 
increased chloride transportation across the cell membrane by improving channel 
gating and thus the time that activated CFTR channels remain open.
The initial phase 3 studies in individuals aged 12 years and older (STRIVE) 
and those aged between 6 and 12 years of age (ENVISION) evaluated ivacaftor or 
placebo in patients with at least one Gly551Asp-CFTR mutation. STRIVE identi-
fied a significant improvement in percentage predicted (pp) FEV1 in the treatment 
arm of 10% at 24 weeks (primary endpoint) that was maintained at 48 weeks. This 
was together with a 3 kg weight gain, an 8-point increase in the Cystic Fibrosis 
Questionnaire Revised (CFQ-R) score (an increase in the score out of 100 reflects 
an improvement in quality of life with a 4-point change being clinically relevant) 
alongside a reduction in sweat chloride to below the definite diagnostic threshold 
for CF to a mean of 47.8 mmmol/l [41]. Similar results were demonstrated in chil-
dren in ENVISION [45]. Participants from both of these studies were then enrolled 
into the open-labeled extension study (PERSIST) where all individuals received 
ivacaftor therapy. These individuals maintained the improvements in lung func-
tion, weight and exacerbation rates at 144 weeks [46].
5.3 Monotherapy for Phe508del mutations
Such exceptional clinical outcomes were a major advancement in the treatment 
options for individuals with CF. However, initially modulator therapy was only 
suitable for approximately 5% of CF individuals as it was only available for gated 
mutations. Agents that could alter abnormal protein trafficking together with CFTR 
channel gating and cell membrane surface stability that results from the Phe508del-
CFTR mutation (class II mutation) would have a far greater impact upon the CF 
community. As multiple stages in the CFTR conformational maturation process are 
affected with the Phe508del-CFTR mutation, different treatment approaches were 
needed.
HTS therefore progressed to evaluating agents that would be suitable for other 
mutation classes, focusing on agents could have an impact on dysfunctional protein 
trafficking [38]. Lumacaftor is an oral corrector agent, which in vitro studies have 
demonstrated can corrects protein misfolding [47]. However, monotherapy with 
either ivacaftor or lumacaftor did not lead to clinically relevant improvements in 
individuals homozygous for the p.Phe508del-CFTR mutation [48, 49].
5.4 Combination therapy: potentiator and corrector agents
As monotherapy only lead to minimal clinically relevant outcomes for 
Phe508del-homozygotes, the argument strengthened for the use of lumacaftor in 
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combination with ivacaftor. Hence, these two therapies were trialed in combination 
(Orkambi®). Phase 3 multicentre studies (TRAFFIC and TRANSPORT) of this 
combination versus placebo elicited a modest gain in absolute pp. FEV1 of 3% at 
24 weeks (primary endpoint) together with significant increases in body mass index 
(BMI) [50]. The lung function increase being comparatively small to that seen with 
ivacaftor for gated mutation. However, importantly the 96-week open label exten-
sion study (PROGRESS), where all individuals within the initial trials received 
lumacaftor in combination with ivacaftor, did demonstrate a 42% reduction in the 
annual rate of lung function decline when compared with matched US registry 
controls [51]. As rate of lung function decline is known to correlate with morbidity 
and mortality, this is still a significant outcome [52, 53].
Although lumacaftor in combination with ivacaftor is associated with stabiliza-
tion of lung disease together with weight improvement, patients can experience 
various side-effects. Respiratory related adverse events were the commonest 
complications in the trials and up to 7% of patients discontinued treatment in 
PROGRESS. In real-world experiences, there have been even higher discontinu-
ation rates of up to 30% [54, 55]. Also, lumacaftor is a potent inducer of the 
CYP3A4 enzymes and can have interactions with various concurrent medications. 
Development of other corrector agents with an improved side-effect profile and the 
potential for enhanced correction of the protein trafficking were therefore required.
This led to the development of tezacaftor, another small molecule correc-
tor agent. Tezacaftor in combination with ivacaftor (Symdeko®/Symveki®), for 
individuals homozygous for the Phe508del-CFTR mutation, when compared with 
placebo resulted in a 4% absolute improvement in ppFEV1, together with a five-
point improvement in CFQ-R scores but without any significant change in BMI 
(EVOLVE). Although the increments in lung function were still not as substantial 
as that seen in ivacaftor use for gating mutations, the adverse events were much 
lower than with lumacaftor/ivacaftor treatment. The discontinuation rate in the 
active treatment arm was only 2.9% and none of these were due to respiratory 
events [56, 57]. It thus appears that the corrector lumacaftor has a poorer side-effect 
profile than tezacaftor, rather than it being a complete class effect. Tezacaftor/
ivacaftor can also be given to patients who have certain residual function and splice 
mutations (E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, 
R352Q , A455E, D579G, 711+3A➔G, E831X, S945L, S977F, F1052V, K1060T, A1067T, 
R1070W, F1074L, D1152H, D1270N, 2789+5G➔A, 3272-26A➔G, 3849+10kbC➔T) 
[58]. Patients with Phe508del and a residual function mutation were studied in the 
phase III trial EXPAND, which was a crossover study where patients either received 
tezacaftor-ivacaftor, ivacaftor monotherapy or placebo. The patients were studied 
for two 8-week intervention periods separated by an 8-week washout period. 
Change in ppFEV1 (the primary endpoint) was greatest in the treatment arms with 
a 6.8% increase with tezacaftor-ivacaftor and 4.7% increase with ivacaftor. Both 
therapies were associated with significant improvements in CFQ-R.
5.5 Future modulator therapy
The combination corrector therapies described, enable individuals with the 
commonest CF mutation the potential of receiving modulator therapy. However, 
lumacaftor/ivacaftor and tezacaftor/ivacaftor do not fully restore CFTR protein 
function. Furthermore, there is still no small molecule therapy for 30% of the 
individuals with CF who are heterozygotes for Phe508del and have a minimal 
function (MF) mutation. MF mutations give rise to either the production of 
defective proteins or no protein production. They include insertion, deletion, 
nonsense and canonical splice mutations. As up to 90% of CF individuals have one 
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Phe508del mutation, if small molecule therapy could significantly increase the 
amount of functional protein for this mutation, a greater range of CF individuals 
could be treated as then the therapy would be suitable for those individuals with the 
Phe508del-MF mutations.
Next generation CFTR correctors are under evaluation in combination with 
tezacaftor/ivacaftor. Phase 2 and 3 trials of these triple therapy agents; VX-659 
and VX-445 have provided further exciting results. These corrector agents have a 
different structure and mechanism of action and provide additive function to the 
other two agents. For individuals homozygous for Phe508del an increase in abso-
lute ppFEV1 was 9.7% for VX-659 treatment and 11% for VX-445 therapy. Greater 
increases in lung function were seen for patients with Phe508del-MF mutations; the 
absolute change in ppFEV1 was 13.3 and 13.8% for VX-659 and VX-445 respectively. 
These increases were also alongside significant improvements in quality of life and 
have been maintained in subsequent phase 3 interim report analyses [59–62]. These 
are incredible outcomes for individuals with more severe mutations and thus who 
typically have more severe disease phenotypes.
6. Implications of modulator therapy
Important advances in the clinical outcomes for individuals with CF have been 
possible since the introduction of modulator therapy. Unfortunately these treat-
ments are currently associated with a substantial cost and as a result are not avail-
able for all eligible patients. In the United States the Food and Drug Administration 
(FDA) has approved all four of the currently available modulator therapies. Some 
European countries and Australia, have access to ivacaftor, lumacaftor/ivacaftor 
and tezacaftor/ivacaftor [63]. However, worldwide there is significant inequality of 
access to these agents.
As an increasing number of modulator agents become available, the CF commu-
nity will need to determine how they can enable patients to receive these expensive 
therapies. If funding bodies are going to approve them, it is likely that they will 
require significant clinical outcomes from their use, especially when funding is 
through a public system.
7. Future directions
The introduction of modulator therapy, particularly when its use becomes 
widespread, is likely to have an impact upon the range of CF phenotypes. The 
amount of phenotypic variations should decrease as fewer patients have significant 
CFTR channel dysfunctional, and it is likely that the disease manifestations will be 
less severe. It is well known that respiratory related CF disease is associated with 
less than 10% CFTR channel function and so there is the potential for modulator 
therapy to have an impact upon this [21]. However, measurements of the degree 
of change in CFTR channel functionally with the use of modulator therapy is not 
being undertaken in the clinical setting. The markers being assessed are all surro-
gate markers of CFTR channel function and include lung function, sweat chloride, 
weight and quality of life questionnaires. Hence, it will be interesting to see the 
long-term impact of significant CFTR modulation on the CF cohort when individu-
als have been on such treatment for many years from birth. Currently a significant 
improvement is felt to be an increase in ppFEV1 greater than 10%. Time will tell as 
to whether such changes have a significant impact upon this long-term multi-system 
disease.
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8. Conclusion
The advancements in CF care over the last decade have been remarkable. The use 
of HTS drug discovery programs have been instrumental in enabling the develop-
ment of the CFTR modulator agents, first the potentiators and subsequently the 
corrector agents. The fact that such therapies target the underlying consequence of 
the CFTR mutation has led to exciting clinical outcomes for individuals with certain 
CFTR mutations because altering the function of the CFTR protein at the molecular 
level is essential for true disease change to occur. “Genetic medicines” require a 
significant improvement in their clinical outcomes before they can become a viable 
option to modulator therapy. They do however have the advantage that they are 
not specific for individual mutation classes and could be used as treatment for all 
patients.
The introduction of newer targeted therapies is transforming CF care, although 
it remains to be seen how these treatments will impact the CF community in the 
longer term. Nevertheless, a shift is starting to occur whereby treatments are 
determined based upon an individual’s genetic mutations. It is likely that this will 
lead to a more personalized model of care and it is hoped a step closer to a cure for 
this life-limiting disease.
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